| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 823.40 | 2.8% |
| Total Income | 823.40 | 2.8% |
| Expenditure | 813.20 | 5.7% |
| PBT | 21.90 | 12.8% |
| Net Profit | 14.40 | 17.2% |
| OPM | 1.24% | 2.73pp |
| NPM | 1.75% | 0.42pp |
| EPS | 0.02 | 81.8% |
Bruker Reports Q1 2026 Revenue of $823.4 Million, Up 2.7% Y-o-Y
06 May 2026 · 6 May, 4:06 pm
Summary
Bruker Corporation reported a 2.7% increase in revenue for Q1 2026, reaching $823.4 million. The company's GAAP diluted earnings per share was $0.02, with a non-GAAP diluted EPS of $0.31. Bruker Scientific Instruments (BSI) saw a high single-digit percentage increase in organic bookings, and the BSI book-to-bill ratio remained above 1.0x for the third consecutive quarter. Bruker reconfirmed its FY2026 revenue guidance of $3.57 to $3.60 billion and non-GAAP EPS guidance of $2.10 to $2.15.
Key Highlights
- 1
Bruker's Q1 2026 revenues reached $823.4 million, reflecting a 2.7% increase year-over-year.
- 2
GAAP diluted earnings per share for Q1 2026 was $0.02, while non-GAAP diluted EPS was $0.31.
- 3
Bruker Scientific Instruments (BSI) bookings in Q1 2026 increased by high-single digits organically year-over-year.
- 4
The BSI book-to-bill ratio remained above 1.0x for the third consecutive quarter.
- 5
The company reconfirmed its FY2026 revenue guidance of $3.57 to $3.60 billion, representing a 4% to 5% year-over-year increase.
- 6
Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind.
Management Comments
Frank H. Laukien
While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bill ratio was again greater than 1.0x. Healthy bookings trends included solid academic orders for our post-genomic research solutions from outside the US, strong AI-driven demand in semiconductor metrology and in SciY laboratory software, bookings strength in industrial research tools and security detection systems. Importantly, we have introduced impactful new products and solutions at recent scientific and medical conferences, further strengthening our leadership position in NMR, leading the way in spatial biology, and innovating in microbiology and molecular diagnostics. With increased visibility, we reconfirm our FY26 guidance, and we expect a return to organic revenue growth in Q2. All in, Bruker remains poised to deliver significant operating margin expansion and double-digit EPS growth in FY2026.
Informational and educational content only. Not investment advice.